How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

399 results for

Clinical Index of Stable Febrile Neutropenia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

361. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma

trials, with variance in clinical and resource estimates of response rates (+/-10%), rates of growth factor use (+/-6%), costs of treatment of febrile neutropenia (an additional $300/responder) and dosage regimen. A comparison was also made using both higher dose and higher efficacy for liposomal daunorubicin and using an assumption of six cycles of treatment for both strategies. Estimated benefits used in the economic analysis Among severely immunocompromised patients with KS who received pegylated (...) of liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology 1998;16:683-691. Gill P S, Wernz J, Scadden D T, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology 1996;14:2353-2364. Indexing Status Subject indexing assigned by NLM MeSH Acquired Immunodeficiency Syndrome /complications; Antibiotics, Antineoplastic

1998 NHS Economic Evaluation Database.

362. Cost-utility analysis of taxane therapy

duration of response was estimated to be six months, the disease being stable for three months and the one year mortality rate was assumed to be 57%. The response duration rates and mortality rates were assumed to be the same for both drugs. It was assumed that 25% of infections and incidents of febrile neutropenia would require hospitalisation. Measure of benefits used in the economic analysis The measure of benefits was Quality Adjusted Life Years (QALYs) gained. A Markov model was used to estimate (...) of effectiveness and key assumptions The frequency of adverse events associated with the use of paclitaxel or docetaxel respectively were as follows: infection, 23% and 26%; febrile neutropenia, 12.5% and 22%; death associated with infection and febrile neutropenia, 1.0% and 0.8%; severe neurotoxicity, 7% and 3.5%; severe fluid retention, 0% and 7%; and severe arthralgia, myalgia or skin reaction, 16% and 12%. The response rates for paclitaxel and docetaxel were found to be 21% and 47% respectively. The median

1997 NHS Economic Evaluation Database.

363. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis

. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001; 44(5): 125-135 PubMedID Other publications of related interest 1. Lau J, Ioannidis JA, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6. 2. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. Indexing Status Subject indexing assigned by NLM MeSH Adult; Amphotericin B /therapeutic use; Antifungal Agents /therapeutic use; Candida (...) , the severity of the underlying illness, the degree of immune suppression of the affected patients, portal of entry of candidaemia, and causative Candida species. Studies comparing fluconazole and amphotericin B for the treatment of antibiotic-refractory neutropenic fever were excluded. Specific interventions included in the review Studies comparing fluconazole with amphotericin B were eligible for inclusion. Studies comparing fluconazole with the combination of amphotericin B and 5-fluorocytosine

2001 DARE.

364. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer

, whereas theZubrod 0 (Karnofsky 100) values were 4% and 11%, respectively. Effectiveness results The median survival was 8.9 months (95% CI: 0 - 20) for the gemcitabine strategy, whereas the corresponding figure for cisplatin and etoposide was 7.3 months (95% CI: 0.4 - 44.8). The 'improved', 'stable' and 'worse' status were, at a midcycle, 9%, 82%, and 9%, respectively for the gemcitabine. The corresponding values for cisplatin and etoposide were 0%, 48%, and 52%, respectively. Clinical conclusions (...) and benefits were not combined since the intervention was regarded as the weakly dominant strategy. The most sensitive variables were febrile neutropenia treatment and the number of days of hospitalization required for administration of chemotherapy, on the part of the comparator. By varying the treatment costs of neutropenia, within the extremes of no occurrence of febrile neutropenia (reported as the most likely scenario) and severe febrile neutropenia, resulted in an increase of 171% in cost savings per

1996 NHS Economic Evaluation Database.

365. Reduced charges and costs associated with outpatient autologous stem cell transplantation Full Text available with Trip Pro

clinic the day after completion of chemotherapy or as soon as clinically stable), and total outpatient transplant (TOT) involving outpatient chemotherapy with outpatient follow-up (pre-hydration and antiemetics followed by chemotherapy administered via a 4 hour infusion into a central venous catheter daily for 4 days in the outpatient setting and discharge to either private home or a local hotel. Patients were seen daily by transplant nurses and physicians and had chemistry and hematology assessment (...) Criteria, days on antibiotics, number of transfusions received, and duration of neutropenia). Length of hospital stay was also compared across the groups. The patient groups were found comparable with regard to Karnofsky performance status (KPS), diagnosis and age. Borderline statistically significant differences were seen with regard to numbers of prior cycles of chemotherapy and pre-transplant albumin, but these were not considered clinically significant. Effectiveness results There were

1998 NHS Economic Evaluation Database.

366. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

benefits and costs. Outcomes assessed in the review The review assessed the following positive outcomes and side-effects associated with each treatment regimen: Overall response rate, stable disease, early progressive disease, infections, hospitalised for infection, febrile neutropenia (FN), hospitalised for FN (3 days), severe neurotoxicity, severe fluid retention, severe arthralgia/myalgia or skin reactions, and death associated with infection and FN. Study designs and other criteria for inclusion (...) with anthracycline-resistant metastatic breast cancer, and the selection of dosage rates appropriate to this category of patient. Results of the review The following outcome results, for docetaxel and paclitaxel respectively,were selected for inclusion in the model: Overall response rate = 47% and 21%, stable disease = 33% and 59%, early progressive disease = 20% for both therapies, infections = 25% and 23%,hospitalised for infection = 25% of infections, febrile neutropenia (FN) = 22% and 12.5%, hospitalised

1996 NHS Economic Evaluation Database.

367. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection

chemotherapy or to a control group. Study design Randomised controlled trial. Analysis of effectiveness The analysis of the clinical study was based on intention to treat. The primary health outcomes used in the clinical study were the incidence (%) and absolute risk reduction (ARR)(%) in febrile neutropenia, renal toxicity and neurotoxicity, and the number of days in hospital. Effectiveness results An absolute risk reduction in febrile neutropenia of 11% (p=0.02) was observed (incidence rate: 21% without (...) amifostine, 10% with amifostine). Renal toxicity was 36% without amifostine compared to 10% with amifostine (p=0.003). This implied an absolute risk reduction of 26%. Neurotoxicity fell from 42% without amifostine to 31% with amifostine (p=0.029, absolute risk reduction of 11%). The total number of days in hospital with febrile neutropenia was 226 for controls and 89 for the amifostine patients (p=0.02). Clinical conclusions Pretreatment with amifostine reduces the cumulative hematologic, renal

1997 NHS Economic Evaluation Database.

368. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy

than 10 x 10^9/L for stable patients; a platelet count of less than 20 x 10^9/L for patients presenting with major bleeding or additional risk factors (pyrexia greater than 38 degrees C, coagulation disorder, or bone marrow biopsy); a platelet count of greater than 20 - 50 x 10^9/L in the present and until the control of major bleeding, soft tissue bleeding requiring red blood cells (RBCs), fresh retinal haemorrhage with impaired vision, disseminated intravascular coagulation, or haemorrhagic (...) of Haematology 2002; 118(2): 677-682 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Aged; Clinical Protocols; Female; Hematologic Neoplasms /drug therapy /economics; Hemorrhage /economics /etiology /prevention & Humans; Male; Middle Aged; Platelet Count; Platelet Transfusion /economics /methods; Prospective Studies; Retrospective Studies; Risk Factors; Thrombocytopenia /prevention & control; control AccessionNumber 22002001338 Date bibliographic record published 31/07/2003

2002 NHS Economic Evaluation Database.

369. Cost effectiveness of treatment options in advanced breast cancer in the UK

and/or intravenous antibacterials, febrile neutropenia with hospitalisation, neutropenia without hospitalisation, death associated with infection or febrile neutropenia, severe neurotoxicity, severe oedema, severe skin condition, and severe nail condition. Study designs and other criteria for inclusion in the review The effectiveness data were derived from a systematic review of randomised controlled trials. Sources searched to identify primary studies Not stated. Criteria used to ensure the validity of primary (...) % with docetaxel, 21% with paclitaxel, and 38.4% with vinorelbine for progressive disease; 8.8% with docetaxel, 4% with paclitaxel, and 10% with vinorelbine for infection with hospitalisation and/or intravenous antibacterials; 7.3% with docetaxel, 7% with paclitaxel, and 0 with vinorelbine for febrile neutropenia with hospitalisation; 10.7% with docetaxel, 10% with paclitaxel, and 0 with vinorelbine for neutropenia without hospitalisation; 1.2% with docetaxel, and 0 with paclitaxel and vinorelbine for death

2001 NHS Economic Evaluation Database.

370. Sequential Study to Treat Renal Cell Carcinoma

months of study Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator; however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study (...) mmHg systolic and/or >= 90 mmHG diastolic on medication). History of HIV infection or chronic hepatitis B or C Active clinically serious infections (> grade 2 NCI-CTC version 3.0) Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry) Patients with seizure disorder requiring medication (such as steroids or anti

2008 Clinical Trials

371. Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets <25,000/μL, ANC <500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment (...) defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1 [ Time Frame: From Baseline up to end of study (assessed up to 55 months) ] CBR is defined as a confirmed CR, confirmed PR, or stable

2008 Clinical Trials

372. Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

plus capeciteabine that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5 (...) participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria

2008 Clinical Trials

373. Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

: disappearance of all index/non-index lesions; PR: >= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present. Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [ Time Frame: From randomization to end of study drug therapy (up to 174 weeks). ] Disease control was defined as the number of participants whose best response was CR, PR, or SD, per the IRRC (...) Recruitment Status : Completed First Posted : June 2, 2005 Results First Posted : October 5, 2010 Last Update Posted : December 24, 2015 Sponsor: Eli Lilly and Company Collaborator: ImClone LLC Information provided by (Responsible Party): Eli Lilly and Company Study Details Study Description Go to Brief Summary: The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than

2005 Clinical Trials

374. Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)

entry. G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity, such as febrile neutropenia, when clinically indicated, or at the discretion of the investigator; however, they may not be substituted for a required dose reduction. Chronic Erythropoietin treatment prior to the study entry or during the study is permitted. Use of ritonavir and grapefruit juice. Prior use of Raf-Kinase inhibitors, MEK or Farnesyl Transferase Inhibitors. Any investigational drug (...) administered as a single agent. Investigators reported seven patients with partial responses, five minor responses and 59 with stable disease for at least 4 months. Median overall survival was 9.2 months and median time to progression 4.2 months. This study showed that Sorafenib was well tolerated and side-effects were manageable and reversible. Rationale 5-Fluorouracil (5-FU) is a widely used agent for patients with unresectable advanced HCC, with objective responses rates around 10%. Compared to bolus

2008 Clinical Trials

375. Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

, or dexamethasone: Nonhematologic ≥ Grade 2 neuropathy with pain ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide) ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy ≥ Grade 4 fatigue persisting > 7 days Treatment delay for toxicity > 21 days Hematologic Grade 4 neutropenia (absolute neutrophil count [ANC] < 500/mm³) > 7 days Febrile neutropenia (ANC < 1,000/mm³ with fever ≥ 38.3ºC) Grade 4 (...) for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 84 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Phase 1b Multicenter Dose Escalation Study of Carfilzomib With Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma Study Start Date : May 2008 Actual Primary Completion Date : May 2013 Actual Study Completion Date : January 2016 Resource links provided

2008 Clinical Trials

376. A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

-hematological toxicity (excluding alopecia) occurring before Day 14 of pomalidomide dosing; febrile neutropenia (absolute neutrophil count [ANC] <1,000/µL and fever >101ºF, core temperature); grade 4 neutropenia of ≥7 days duration with onset on or before Day 14 of pomalidomide dosing; platelet count <25,000/µL occurring before Day 14 of pomalidomide dosing. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0, grades: 1=mild, 2=moderate, 3=severe, 4=life (...) of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer. Condition or disease Intervention/treatment Phase Carcinoma, Small Cell Drug: Pomalidomide Drug: Cisplatin Drug: Etoposide Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 22 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose

2007 Clinical Trials

377. Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

States, 22908 Sponsors and Collaborators Mayo Clinic National Cancer Institute (NCI) Investigators Layout table for investigator information Study Chair: Clive S. Zent, MD Mayo Clinic More Information Go to Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Mayo Clinic ClinicalTrials.gov Identifier: Other Study ID Numbers: LS0881 LS0881 ( Other Identifier: Mayo Clinic Cancer Center ) 08-000673 (...) . ClinicalTrials.gov Identifier: NCT00669318 Recruitment Status : Completed First Posted : April 30, 2008 Results First Posted : June 20, 2014 Last Update Posted : July 1, 2014 Sponsor: Mayo Clinic Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Mayo Clinic Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy, such as pentostatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping

2008 Clinical Trials

378. A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)

to study drug that prevented escalation of the drug dose. Hematologic DLTs were any grade (Gr) 4-5 toxicity EXCEPT: Gr 4 anemia and Gr 4 leukopenia, Gr 4 neutropenia lasting for <7 days, Gr 4 thrombocytopenia lasting for <4 days except if a platelet transfusion is required, and Gr 3/Gr 4 neutropenia with fever >38.5°C and/or infection requiring antibiotic or anti-fungal treatment. Non-hematologic DLT was defined as any Gr 3, 4, or 5 non-hematologic toxicity EXCEPT: nausea, vomiting, diarrhea (...) they are clinically stable for 1 month prior to entry Has a primary central nervous system tumor Is allergic to any of the components of the combination study therapy or its analogs Participant has had prescription or non-prescription drugs or other products known to be metabolized by Cytochrome P450 3A4 (CYP3A4) that cannot be discontinued prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication. Medications of particular concern are inhibitors of CYP3A4

2008 Clinical Trials

379. Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

], version 3.0: neutropenia (lasting >5 days), febrile neutropenia, documented infections related to neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events; or death due to any cause. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored for this analysis at the date of last contact. Survival Without Grade 4 Toxicity [ Time Frame: Baseline to until 218 events (defined as death or Grade 4 toxicity) have been observed (...) to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 260 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Study Start Date : October 2007 Actual Primary Completion Date

2007 Clinical Trials

380. The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

is currently enrolling. Phase I trial patients will have weekly laboratory evaluations and clinical evaluation every three weeks. Phase II trial patients will have laboratory evaluations on day one and day eight and clinical evaluation every three weeks. The maximum duration of the trial is one year of therapy. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 19 participants Intervention Model: Single Group Assignment Masking: None (Open (...) to Primary Outcome Measures : Number of Patients Free of Dose Limiting Toxicity [ Time Frame: 21 days ] A dose limiting toxicity was defined as an adverse event or laboratory abnormality that occurs to patients on the Phase I portion of the trial, during the first 21 days following the first dose of RAD001/docetaxel during cycle 1, judged to be related to RAD001/docetaxel and meeting any of the following criteria: Hematologic Toxicity: CTCAE grade 4 neutropenia > 7 days or any Grade 3 or 4 neutropenia

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>